Ripple Neuro

Ripple Neuro runs a hardware-plus-recurring-services model: labs pay an upfront capital expenditure for a neural recording system and then place repeat orders for consumable microelectrode arrays and support contracts. Its core products — the Grapevine and Trellis systems — are high-channel-count electrophysiology platforms sold to academic neuroscience labs, pharmaceutical R&D groups, and early-stage clinical BCI programs. Revenue is recognized at point of sale for the hardware and ratably over the life of service agreements or as consumable electrodes are shipped. The structural economics mirror those of scientific instrument companies. The hardware carries high gross margins typical of specialized capital equipment, but the real compounding lever is the consumable attach rate: each installed system creates a recurring pull for replacement electrode arrays, surgical accessories, and annual maintenance plans. The software that runs the recording interface is bundled with the hardware, so there is no separate SaaS line item — though software updates function as a retention mechanism. Customer acquisition cost is high because sales cycles involve lengthy procurement processes at universities and NIH-funded labs, but switching costs are also high once a lab builds its experimental protocols around a given system. No public financial data is available, but the model structurally resembles that of established neurophysiology tool vendors where hardware acts as a loss leader or low-margin anchor for high-margin consumables and service revenue over the system's useful life.